ReAlta Life Sciences, Inc. ReAlta Life Sciences, a clinical stage company focused on rare diseases, has developed a novel class of drugs with unique dual-targeting therapeutic capabilities that rebalance complement and inflammatory processes
ReAlta Life Sciences Strengthens Board of Directors with Appointment of . . . Norfolk, VA – January 3, 2024 – ReAlta Life Sciences, Inc (“ReAlta” or the “Company”), a mid-stage clinical biotech company dedicated to saving lives by rebalancing the inflammatory response to address life-threatening diseases, today announced the appointment of three seasoned biotechnology executives, Christi Shaw, Mert Aktar
ReAlta Life Sciences Announces New Inflammatory Biomarker Data from . . . ReAlta’s therapeutic peptides employ the dual-targeting mechanisms of HAstV-1 to modulate both complement and innate inflammatory pathways by inhibiting complement cascade activation and two key neutrophil-driven mechanisms: myeloperoxidase (MPO) and neutrophil extracellular traps (NETs)
Board of Directors - Realta Life Sciences ReAlta Life Sciences is a clinical stage biotech company, dedicated to saving lives by rebalancing the inflammatory response through our EPICC technology platform
About Us - Realta Life Sciences ReAlta Life Sciences is a clinical stage biotech company, dedicated to saving lives by rebalancing the inflammatory response through our EPICC technology platform
News about ReAlta Life Sciences ReAlta Life Sciences Announces New Clinical Data for RLS-0071 (pegtarazimod) from Hypoxic Data confirm elevated inflammatory biomarkers in newborns with Hypoxic Ischemic Encephalopathy (HIE) and demonstrate a predictable pharmacokinetic profile for RLS-0071
Management Team - Realta Life Sciences ReAlta Life Sciences is a clinical stage biotech company, dedicated to saving lives by rebalancing the inflammatory response through our EPICC technology platform
ReAlta Life Sciences Announces Appointment of Distinguished . . . ReAlta’s therapeutic peptides employ the dual-targeting mechanisms of HAstV-1 to modulate both complement and innate inflammatory pathways by inhibiting complement cascade activation and two key neutrophil-driven mechanisms: myeloperoxidase (MPO) and neutrophil extracellular traps (NETs)
ReAlta Life Sciences Announces New Clinical Data for RLS-0071 . . . ReAlta’s therapeutic peptides employ the dual-targeting mechanisms of HAstV-1 to modulate both complement and innate inflammatory pathways by inhibiting complement cascade activation and two key neutrophil-driven mechanisms: myeloperoxidase (MPO) and neutrophil extracellular traps (NETs)